Beone Medicines is a global oncology company discovering and developing treatments for cancer, with a primary focus on hematology and solid tumors. The company's core franchise in chronic lymphocytic leukemia (CLL) includes the Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA (zanubrutinib), the B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax, and the BTK chimeric degradation activation compound (BTK-CDAC) BGB-16673. Its solid tumor portfolio features the anti-PD-1 antibody TEVIMBRA (tislelizumab) and investigational assets including the CDK4 inhibitor BGB-43395, the B7-H4 antibody-drug conjugate BG-C9074, the GPC3-dependent 4-1BB bispecific T-cell engager BGB-B2033, the PRMT5 inhibitor BGB-58067, and the CEA ADC BG-C477. Beone Medicines operates an integrated model with in-house clinical development and manufacturing capabilities across the U.S., China, the UK, and Australia. The company serves markets in the U.S., Europe, Japan, Korea, and Brazil, and has established partnerships with Amgen, Novartis, and Celgene. Founded in 2010 by John V. Oyler and Xiaodong Wang, the company was formerly known as BeiGene.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage beonemedicines.com
Sector Healthcare IR page ir.beonemedicines.com
Tags
oncology, hematology, solid tumors, btk inhibitors, bcl2 inhibitors, antibody-drug conjugates, bispecific antibodies, protein degraders, cll, mantle cell lymphoma, lung cancer, breast cancer, BRUKINSA, zanubrutinib, sonrotoclax, BGB-16673, TEVIMBRA, tislelizumab, BGB-43395, BG-C9074, BGB-B2033, BGB-58067, BG-C477, lifirafenib, pamiparib, BGB-3111, BeOne Care Foundation
Press page beonemedicines.com/newsroom

Metrics

Valuation  
Market cap $ 602.148B
Market cap (USD) $ 602.148B
P/E 665.49
PEG —
P/BV 103.45
P/S 91.14
P/OCF 378.66
P/FCF 415.49
Dividend yield —
Turnover / mcap —
Returns  
ROE 7.5%
ROI 5.3%
ROIC 5.7%
Profit margin 5.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 18.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 38
Quality score 5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 5.343B 3.81B 2.459B 1.416B 1.176B 308.874M 428.212M 198.22M 238.387M 1.07M 8.816M
Net profit 286.933M -644.786M -881.708M -2.004B -1.413B -1.597B -948.628M -673.769M -93.105M -119.217M -57.102M
Free cash flow 941.741M -633.294M -1.719B -1.822B -1.562B -1.401B -839.881M -618M -33.622M -113.015M -45.157M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 303.81 184.71 180.36 219.94 270.93 258.39 165.76 140.26 97.72 30.36 —
Price performance 12m 0.64 0.02 -0.18 -0.19 0.05 0.56 0.18 0.44 2.22 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 29.4M 41.1M 70.9M 60.4M 483M 173M 358M 676M 865M
↳ YoY growth +39.5% +72.6% -14.8% +699.8% -64.2% +106.8% +88.9% +27.9%
↳ 5y CAGR +42.5% +54.2% +57.0% +70.3%
Borrowings, current (USD) — 9.22M 8.73M 0.00 670M 428M 329M 688M 852M 66.4M
Borrowings, non-current (USD) 17.3M 9.22M 40.8M 83.3M 184M 202M 209M 198M 166M 962M
Lease liabilities (USD) — — 27.4M 36.6M 43.3M 65M 58.6M 44.2M 61.9M 73.6M
Cash and deposits (USD) 87.5M 240M 713M 618M 1.38B 4.38B 3.87B 3.17B 2.63B 4.55B
Intangible assets (USD) — 7.25M 7.17M 5.85M 5M 46.7M 40.6M 57.1M 51.1M 62.7M
Right-of-use assets (USD) — 12.5M 45.1M 82.5M 90.6M 117M 110M 95.2M 139M 148M
Net debt (borrowings + leases - cash) (USD) -70.2M -221M -663M -498M -485M -3.68B -3.27B -2.24B -1.55B -3.45B
Cash flow detail
Operating cash flow (USD) -89.5M 12.8M -548M -750M -1.28B -1.3B -1.5B -1.16B -141M 1.13B
Purchases of property, plant and equipment (USD) -23.5M -46.4M -70.3M -89.6M -118M -263M -325M -562M -493M -186M
Purchases of intangible assets (USD) 0.00 0.00 -553,000 0.00 0.00 -43.4M 0.00 -19.4M -4.67M -20M
Change in receivables (cash effect) (USD) 0.00 -29.4M -11.6M -29.8M 10.4M -423M 304M -188M -329M -165M
Change in inventories (cash effect) (USD) 0.00 -10.9M -5.31M -12.3M -58.9M -153M -56.7M -141M -91.5M -93.2M
Change in payables (cash effect) (USD) 2.71M 55.3M 23.5M 2.22M 95.8M 20M -4.35M 21.5M 121M 79.8M
Interest paid (cash effect) (USD) -826,000 -1.26M -2.21M -4.32M -44.1M -30M -25.2M -19.8M -19.7M -34.4M
Income taxes paid (cash effect) (USD) -25,000 -29.3M -12.4M -8.98M -10.6M -15.7M -29.5M -56M -69.4M -101M
Share-based compensation (USD) 10.6M 42.9M 87.1M 134M 183M 241M 303M 368M 442M 511M
Operating cash flow before change in receivables (USD) -89.5M 42.2M -536M -720M -1.29B -876M -1.8B -969M 189M 1.29B
Free cash flow (OCF - PPE - intangibles) (USD) -113M -33.6M -619M -840M -1.4B -1.61B -1.82B -1.74B -638M 922M
Income detail
Research and development expense (USD) 98M 269M 679M 927M 1.29B 1.46B 1.64B 1.78B 1.95B 2.15B
↳ 5y CAGR +119.1% +111.6% +85.9% +71.6% +43.6% +21.2% +16.1% +10.6%
Total comprehensive income (USD) -118M -92.7M -672M -960M -1.59B -1.4B -2.1B -904M -694M 358M
Comprehensive income to owners (USD) -118M -92.6M -672M -958M -1.58B -1.4B -2.1B -904M -694M 358M
Provision for credit losses (USD) — — — — 109,000 309,000 -219,000 — — —
Credit cost ratio (credit losses / average receivables) (%) — — — — 0.2% 0.1% 0.1% — — —
Reported Feb 28, 2019 Feb 28, 2019 May 9, 2019 Mar 2, 2020 Feb 25, 2021 Feb 28, 2022 Feb 27, 2023 Feb 27, 2025 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Beone Medicines Ltd. (ticker 6160), listed in United States.

Company History

Date Change Detail
May 27, 2025 Renamed BEIGENE, LTD. → BEONE MEDICINES LTD.
— Former tickers BGNE

ETFs Holding Beone Medicines Ltd.

ETF Weight in ETF Shares Market value As of
CANC 3.18% 18,669 $ 6.713M Aug 31, 2026
SAGP 1.63% 57,500 $ 1.249M Jun 30, 2026
PCCE 1.12% 800 $ 17.382K Jun 30, 2026
CGGO 0.85% 240,864 $ 99.065M Nov 16, 2026
CGGE 0.82% 64,959 $ 26.717M Nov 16, 2026
CGIE 0.70% 41,231 $ 16.958M Nov 16, 2026
CGNG 0.68% 48,251 $ 19.845M Nov 16, 2026
FEMR 0.64% 37,464 $ 1.011M Jun 30, 2026
EMEQ 0.61% 14,328 $ 4.083M Jun 30, 2026
TMED 0.40% 322 $ 91.76K Jun 30, 2026
FFEM 0.36% 711 $ 224.683K Jul 31, 2026
HELX 0.23% 225 $ 64.118K Jun 30, 2026
APIE 0.19% 6,192 $ 2.227M Aug 31, 2026
DFAE 0.18% 311,330 $ 16.182M Nov 12, 2026
DFSE 0.15% 8,670 $ 884.576K Nov 12, 2026
AVSE 0.15% 7,703 $ 318.867K Nov 16, 2026
TIER 0.15% 2,100 $ 51.912K Jul 31, 2026
NTSE 0.14% 273 $ 77.797K Jun 30, 2026
REMG 0.13% 6,600 $ 143.397K Jun 30, 2026
AVEM 0.11% 744,667 $ 27.651M Nov 16, 2026
FTLS 0.10% 6,527 $ 0.00 Nov 16, 2026
DFEM 0.10% 61,403 $ 8.52M Nov 12, 2026
DEHP 0.09% 2,501 $ 350.283K Nov 12, 2026
JSTC 0.08% 586 $ 241.016K Nov 17, 2026
DFAX 0.02% 44,007 $ 2.434M Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
ONC canonical Common share — US nasdaq 405.95 USD 2026-11-06
6160 Common share — HK hkex 242.60 HKD 2026-11-19
BEIGF Common share — US otc — —